Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 6/20 | 0.52 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | GGPS1 | O95749 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ADH1C | P00326 | 1/20 | 0.36 |
| ▸ | ADH1A | P07327 | 1/20 | 0.36 |
| ▸ | ADH4 | P08319 | 1/20 | 0.36 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11861174 | 1.00 | DNM1 (0.52) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL32661414 | 1.00 | DNM1 (0.52) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL29374911 | 1.00 | DNM1 (0.52) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL4540276 | 0.97 | — | — | |
| SCHEMBL1578060 | 0.90 | — | — | |
| SCHEMBL7130140 | 0.89 | ALDH1A1 (0.42) | DNM1TSHRALDH1A1 | |
| SCHEMBL3501059 | 0.78 | — | — | |
| SCHEMBL11416179 | 0.77 | DNM1 (0.48) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL10793051 | 0.77 | DNM1 (0.48) | DNM1S1PR2S1PR1S1PR3S1PR5 | |
| SCHEMBL11554162 | 0.77 | DNM1 (0.48) | DNM1S1PR2S1PR1S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 805 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121762836-B | Nucleic acid aptamer-based salmonella paratyphi A biosensor and preparation method thereof | 深圳海关食品检验检疫技术中心 | 2026-05-19 | — | — | CN | claimed |
| WO-2025264860-A2 | METHODS OF TREATING POST-COVID AIRWAY DISEASE | YALE UNIVERSITY (US) | 2025-12-26 | — | — | WO | claimed |
| US-20250222027-A1 | CYTOKINE RECEPTOR AGONIST AND VIRAL VECTOR COMBINATION THERAPIES | SANA BIOTECHNOLOGY, INC. (US) | 2025-07-10 | — | — | US | claimed |
| CN-120078878-A | Application of Tim-3 protein in treating liver injury | 复旦大学附属中山医院 | 2025-06-03 | — | — | CN | claimed |
| US-20250146082-A1 | Methods for Enriching Microbial Cell-Free DNA in Plasma | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-05-08 | — | — | US | claimed |
| CN-119162383-A | Multiplex PCR primer and probe combination for detecting 7 high-risk human papilloma virus E6/E7 region DNA/mRNA, detection method and kit using combination | 海宁奥羚医学检验实验室有限公司 | 2024-12-20 | — | — | CN | claimed |
| CN-119156405-A | Use and method of IL-2, IL-13 and IL-4 cytokine bifunctional molecules | 梅迪塞纳医疗股份有限公司 | 2024-12-17 | — | — | CN | claimed |
| US-20240300972-A1 | THIOPHENE-BASED LIPIDS | OREGON STATE UNIVERSITY (US) | 2024-09-12 | — | — | US | claimed |
| CN-118147053-A | Culture system, kit and method for inducing mesenchymal stem cells | 成都赛济元生物医药有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-118103340-A | Method for manufacturing medical injection device and medical injection device manufactured by same | 斯特瓦纳托集团有限公司 | 2024-05-28 | — | — | CN | claimed |
| WO-2023122721-A2 | PEPTIDES FOR CELL-TYPE SPECIFIC TARGETING OF THE RETINA | OREGON STATE UNIVERSITY (US) | 2023-06-29 | — | — | WO | claimed |
| US-11679165-B2 | Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-20 | — | — | US | claimed |
| EP-4172216-A1 | BIFUNCTIONAL SUPERKINES AND USES THEREOF | Medicenna Therapeutics, Inc. (CA) | 2023-05-03 | — | — | EP | claimed |
| CN-109477074-B | Improved influenza b virus replication for vaccine development | 威斯康星旧生研究基金会 | 2023-01-24 | — | — | CN | claimed |
| CN-115452907-A | Preparation method of competitive lead ion photoelectrochemical aptamer sensor | 苏州清梭环境科技有限公司 | 2022-12-09 | — | — | CN | claimed |
| CN-111122847-B | Method for rapidly detecting aflatoxin B1 on site based on aptamer | 福建中医药大学 | 2022-09-20 | — | — | CN | claimed |
| US-20220145389-A1 | METHODS AND COMPOSITIONS USEFUL FOR NUCLEIC ACID ANALYSIS | WATERS TECHNOLOGIES CORPORATION | 2022-05-12 | — | — | US | claimed |
| WO-2022098819-A1 | METHODS AND COMPOSITIONS USEFUL FOR NUCLEIC ACID ANALYSIS | WATERS TECHNOLOGIES CORPORATION (US) | 2022-05-12 | — | — | WO | claimed |
| CN-110856158-B | Method and system for realizing one card and two numbers of China telecommunication number and foreign operator number | 上海欣方智能系统有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-114134176-A | Construction of whitefly gene silencing system induced by geminivirus DNA1 molecule | 沈阳农业大学 | 2022-03-04 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240300972-A1 | THIOPHENE-BASED LIPIDS | CETP, APOB, PLTP | DNM1 2559/4885S1PR2 1259/4885S1PR1 1146/4885 |
| US-11679165-B2 | Alkenyl substituted 2,5-piperazinediones, compositions, and uses thereof | UGT1A10, AKR1B10, CCR10 | DNM1 4769/4885S1PR2 198/4885S1PR1 179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.